Taken together, these studies suggest that pharmacological ATX inhibition or ATX gene silencing protect against cardiac hypertrophy, fibrosis, and mitochondrial dysfunction, thus preserving systolic function during diet-induced obesity. The gene discussed is ENPP2; the disease is cardiac hypertrophy.